Influenza viruses mutate frequently, necessitating constant updates of vaccine viruses. To establish experimental approaches that may complement the current vaccine strain selection process, we selected antigenic variants from human H1N1 and H3N2 influenza virus libraries possessing random mutations in the globular head of the haemagglutinin protein (which includes the antigenic sites) by incubating them with human and/or ferret convalescent sera to human H1N1 and H3N2 viruses. We also selected antigenic escape variants from human viruses treated with convalescent sera and from mice that had been previously immunized against human influenza viruses. Our pilot studies with past influenza viruses identified escape mutants that were antigenically similar to variants that emerged in nature, establishing the feasibility of our approach. Our studies with contemporary human influenza viruses identified escape mutants before they caused an epidemic in 2014-2015. This approach may aid in the prediction of potential antigenic escape variants and the selection of future vaccine candidates before they become widespread in nature.
T he haemagglutinin (HA) protein is the major influenza viral antigen 1 and the primary target of infection-neutralizing antibodies. During influenza virus circulation in humans, the antigenicity of the virus gradually changes due to mutations in the globular head of HA, necessitating frequent updates of the influenza vaccine 2, 3 . Selection of antigenic variants of influenza viruses in humans is believed to be driven by neutralizing antibodies 4 . Currently, seasonal influenza vaccine strains are selected based on the antigenicity of clinical isolates and cross-reactive immunity in human populations in combination with genetic and epidemiological data 5 . This decision has to be made more than six months before the onset of the influenza season to allow sufficient time for vaccine manufacture. At the time of decision making, novel antigenic clusters may not have emerged or may not yet be recognized, occasionally resulting in the selection of vaccine strains that differ antigenically from the viruses circulating during the subsequent influenza season, leading to low vaccine effectiveness 6, 7 . Presently, no experimental or computational methods exist to predict future antigenic variants before they emerge in nature. We have therefore developed an experimental strategy to predict the antigenic evolution of human influenza A viruses.
In our approach ( Fig. 1) , mutant virus libraries with random mutations in the antigenic region of HA are screened in vitro with antisera against circulating viruses or in mice immunized against the circulating viruses. The antigenic properties of the escape mutants are analysed by using haemagglutination inhibition (HI) assays. Antigenic cartography (an established method to visualize and analyse HI data 8 ) is then used to identify novel antigenic clusters that may necessitate the update of an influenza vaccine. This experimental approach could identify novel antigenic clusters before they emerge in nature and complement the current vaccine selection process.
Antigenic evolution of A(H1N1)pdm09 viruses
First, we performed a proof-of-concept study to identify and characterize antigenic escape variants to pandemic (H1N1) 2009 influenza A (A(H1N1)pdm09) viruses. Eight convalescent sera collected from A(H1N1)pdm09-infected individuals in Japan (Supplementary Table 1) were mixed with two A(H1N1)pdm09 clinical isolates and escape viruses were isolated using plaque assays in Madin-Darby canine kidney (MDCK) cells. Escape mutants possessed the K153E/N239K, D127E or K163E mutations (H1 numbering; Supplementary Table 2) . HI assays with ferret antisera against the escape variants confirmed that they were antigenically distinct from their parental viruses (Supplementary Table 3 ).
To further explore the antigenic landscape, we generated a virus library with random mutations in the HA globular head (encompassing amino acids 54-253; Supplementary Fig. 1 Fig. 1 and Supplementary Table 6 ). These HA mutant libraries were individually screened with ferret antisera as shown in Supplementary  Table 7 . Libraries for which we did not have escape mutant-specific antisera (HA positions 141, 142, 152, 186, 187 and 190) were screened with antiserum to wild-type virus, and libraries for which we isolated antigenic escape mutants in our earlier experiments (namely, HA positions 125, 127, 129, 153, 154, 155, 156, 163 and 183) were screened with antisera to the N125D, D127E, N129D, K153E, K154N, G155E, N156D, K163E or S183P escape mutants, respectively, to obtain additional mutants at the respective positions. For each screen, at least 11 plaque-purified viruses were characterized for their HA sequence and antigenicity (Supplementary Table 8 ). Mutations at positions 153-156 reduced HI titres up to 16-fold, suggesting that these HA positions play a major role in A(H1N1)pdm09 HA antigenicity. We did not identify antigenic escape mutants at positions 141, 163 or 187.
Our data suggested a key role for amino-acid positions 153-156 in A(H1N1)pdm09 antigenicity. We therefore generated HA mutant libraries with random mutations at two, or all four, of these positions (Supplementary Table 6 ). Random mutations at positions 153-156 were also combined with the D127E mutation in HA. This mutation is located near the Sa antigenic site, was selected in our screens (Supplementary Tables 2 and 5 ) and has been detected in several natural A(H1N1)pdm09 isolates. Virus libraries possessing mutations at two sites were screened with 50:50 mixtures of antisera against Table 7 ). More than 320 escape mutants were isolated that exhibited reduced reactivity with antiserum against the wild-type virus (Supplementary Tables 9-11 ). Among those, certain amino acid changes were found at higher frequency (for example, the N156G mutation). Sequence analysis of mutagenized plasmids used for virus library generation did not show sequence biases (Supplementary Tables 12 and 13 ), so more frequently detected variants were most likely selected due to immune pressure and/or structural changes that conferred a fitness advantage. We also carried out antigenic selection studies in which A/California/04/2009 virus-infected mice (Supplementary  Table 14) were challenged with the mutant HA virus library possessing random amino acid changes at positions 153-156 together with the D127E mutation. We sequenced the HA gene of 53 escape viruses and detected several amino acid combinations that had also been selected in our in vitro antigenic selection experiments (Supplementary Table 15 ). These findings suggest that our in vitro selection experiments with human sera in part reflect in vivo immune evasion mechanisms.
To obtain a comprehensive picture of the antigenic properties of selected escape variants, 469 viruses (including 447 HA escape variants selected in this study) were characterized in HI assays with a panel of ferret antisera against H1N1 influenza viruses (Supplementary Table 16 ). The HI data were then analysed using antigenic cartography 8, 13, 15, 16 . Many of the escape mutants form a single cluster approximately four antigenic units (representing a 16-fold reduction in HI titre) away from wild-type A/Norway/ 3858/2009 virus (Fig. 2a) . Thus, although our in vivo selection studies resulted in the isolation of 28 different combinations of amino acid changes (Supplementary Table 15 ), they all localized to the same novel antigenic cluster. Mutations at positions 153-156 had the greatest impact on antigenicity ( Fig. 3) . Importantly, single amino acid changes are sufficient to produce antigenic variants with >16-fold difference in HI titre ( Fig. 2b and Supplementary Fig. 2 ).
To exclude the possibility that the antisera did not adequately resolve the antigenicity of the escape mutants in the antigenic cluster we identified, we raised additional ferret antisera against ten antigenic variants that lie in the new cluster or were outliers of the original cluster (Supplementary Fig. 3 and Supplementary  Table 17 ). HI assays with these antisera did not result in appreciable changes to overall relationships or placement of any of the viruses ( Supplementary Fig. 3b ). Thus, the identification of only one new antigenic cluster is a valid finding and not an artefact of poor resolution of antigenic differences by the antisera used in this study. Further analysis also revealed that the accumulation of mutations at positions tested here resulted in viruses that are increasingly distinct from the parental virus ( Supplementary Fig. 4 ). However, the effect of individual mutations cannot be summed to predict the effect of combinations of mutations ( Supplementary Fig. 5 ).
Our study identified several potential A(H1N1)pdm09 escape variants, so we analysed the antigenicity of 2,555 recently circulating A (H1N1)pdm09 strains derived from routine WHO surveillance from 2009 to 2013. Isolates from each season were analysed separately due to the lack of common antigens and antisera between the data sets ( Fig. 2c and Supplementary Fig. 6a -e). Over 6% of the strains were antigenically different (that is, more than fourfold difference in HI titre) from the vaccine strain, A/California/07/2009. The antigenic variation seen among these viruses was representative of that seen in A (H1N1)pdm09 viruses currently circulating worldwide 17 . The antigenic differences found were identical to those identified with experimentally selected antigenic variants in this study in terms of distance and direction from the main antigenic cluster (typified by the vaccine strain) as well as the formation of a single antigenically distinct cluster. No mutations at any of the other sites identified by Koel et al. were observed 13 . All but two of the antigenic variants identified among circulating strains contained mutations shown in this study to cause antigenic change (K153E, K154E, G155E or N156D). The exceptions were two isolates of the same virus: egg-passaged A/Iraq/8529/2009 (E3) and MDCK cell-passaged A/Iraq/8529/2009 (MDCK1). To directly compare the two data sets, we tested 20 field viruses against a subset of ferret antisera used in this study and generated a new antigenic map that merged the data sets from both experimentally generated mutants (Fig. 2b) and field strains (Fig. 2c) (combined data are shown in Fig. 2d , and a zoomable version is provided in Supplementary Fig. 6f ). Isolates that were antigenically advanced, but had no sequence information, were subsequently sequenced. The antigenic properties of these viruses were consistent between the two data sets and demonstrated that a laboratory-based antigenic selection procedure can produce variants seen in surveillance samples.
Our experimental data demonstrate that the amino acids at positions 153-156 of HA are critical for antigenicity. This finding is consistent with several studies showing that a small proportion of A(H1N1)pdm09 clinical strains with amino acid changes in HA positions 153-157 showed antigenic drift compared with the A/California/07/2009-like reference viruses [18] [19] [20] . Moreover, mutations at positions 153-157 of HA have been detected after in vitro passage of A(H1N1)pdm09 viruses in the presence of monoclonal antibodies 21, 22 or after A(H1N1)pdm09 passage in suboptimally vaccinated ferrets 20 . HA positions 153-156 are located at the edge of the receptor-binding pocket; hence, the amino acids at these positions may affect receptor-binding avidity and specificity 20, 23 , in addition to antigenicity.
To determine whether the HA mutants selected in our study and the field strains from the new antigenic cluster could indeed evade immunity to current A(H1N1)pdm09 strains, mice were immunized by infection or vaccination with an A(H1N1)pdm09 virus ( Supplementary Figs 7 and 8) . Four weeks later, the mice were challenged with the viruses indicated in Supplementary Figs 9 and 10 (also Supplementary Tables 18 and 19 Figs 9 and 10 ). By contrast, 12 of the 13 antigenic variants tested replicated in the lungs of immunized mice. Similarly, several viruses representing antigenic variants isolated in our study and found in field strains also replicated in mice immunized against current A(H1N1)pdm09 viruses ( Supplementary Fig. 10 ).
Next, we tested whether the selected antigenic variants could evade immunity to the current A(H1N1)pdm09 viruses in ferrets, a commonly used animal model in the evaluation of influenza vaccines. Ferrets were immunized by infection with A/California/04/2009 virus. Pre-challenge serum HI titres were between 1:160 and 1:640 ( Supplementary Fig. 11 ). Twelve months later, ferrets were challenged with either A/California/ 04/2009 control virus, three different mutant viruses that replicated in mice immunized with wild-type virus (Fig. 4) virus or with the A/California/07/2009 split vaccine) (Fig. 4) . No virus was detected from the nasal washes collected from the immunized ferrets challenged with A/California/04/2009 virus. By contrast, the three antigenic mutants identified in our in vivo screens and the antigenic mutant with HA changes found in the field strain replicated efficiently in immunized ferrets. Thus, viruses possessing these mutations in HA may have the potential to cause epidemics in the future.
As influenza viruses evolve and amino acid substitutions become fixed within an antigenic cluster, these changes in genetic background may affect the future evolution of the viruses. If so, antigenic evolution studies should be updated repeatedly with contemporary viruses.
Retrospective antigenic evolution of H3N2 viruses
To further test the potential of our experimental approach to identify future antigenic drift of influenza viruses, we carried out a retrospective study with human H3N2 viruses, whose antigenic evolution is well characterized 8, 13, 24, 25 . The antigenic transition from the Sydney/1997 (SY97) cluster to the Fujian/2002 (FU02) cluster required two amino acid changes: HA-H155T and HA-Q156H Tables 18 and 19 ). Shown are nasal wash virus titres collected from day 1 to day 5 post-challenge (all nasal wash samples collected on days 6-8 post-challenge were negative for virus). Dashed lines, virus detection limit (log 10 (p.f.u. ml Tables 20 and 21 ). All Kwangju/219 mutants that inherently encoded HA-155T and acquired the HA-Q156H mutation localized to the edge of the FU02 cluster (Fig. 5, red triangles) . Most CUHK5250 mutants did not shift to the FU02 cluster, as expected by the absence of the HA-H155T-Q156H mutations. However, one CUHK5250 mutant possessing HA-Q156H-H183L mutations mapped to the outer edge of the FU02 cluster (Fig. 5, red rhombus) . This variant is located in the antigenic map close to the cluster of Kwangju/219 mutants encoding HA-155T-156H (Fig. 5, red triangles) . Hence, our in vitro antigenic selection identified the same antigenic drift mutants that occurred in nature (that is, HA-H155T-Q156H) and were critical for the transition from the SY97 cluster to the FU02 cluster. 29 . To identify antigenically advanced variants of contemporary human H3N2 viruses, we generated a virus library possessing random amino acid changes at HA positions 63-252 (H3 numbering) of TX/50, the WHO-recommended vaccine virus at that time. The library was screened with ten human antisera collected in December 2013-January 2014 and with three mixtures of these antisera based on the age of the donor (Supplementary Table 22) . We identified 139 different potential escape mutants (Supplementary  Tables 23 and 24) ; the most frequently mutated amino acid position was HA-159, consistent with the role of this amino acid position in recent cluster transitions. For antigenic analysis, we chose a subset of 24 antigenic mutants that encoded amino acid changes frequently detected in these screens and/or amino acid changes known to affect antigenicity (indicated by HI titres in Supplementary Tables  23 and 24 ). HI assays were conducted in the presence of 20 nM oseltamivir with 19 reference antisera and with 19 reference strains. The resulting HI data were merged with data from the Centers for Disease Control and Prevention (CDC) (Fig. 6) . The TX/50 antigenic cluster (encoding HA-159F; blue) and the minor 3C.3b cluster (also encoding HA-159F, yellow) are antigenically closely related, whereas the 3C.3a cluster (characterized by HA-159S; green) and the now dominant 3C.2a cluster (characterized by HA-159Y; red) are antigenically distinguishable from TX/50. Among the experimentally derived escape variants (shown in numbered mid-sized circles), the majority of antigenically 'advanced' mutants (that is, those that shifted from the vaccine virus by more than two grid units (four HI units)) moved towards are known to affect antigenic and receptor-binding specificity, respectively 13, 30, 31 . The HA-N225D mutation is present in most viruses belonging to clade 3C.2a; however, the HA-K189E mutation has not been detected in human H3N2 influenza viruses collected from 1 January 2014 to 20 February 2016, based on sequence searches in GISAID (http://platform.gisaid.org) and the Influenza Research Database (www.fludb.org). Collectively, these findings indicate that although our approach may not always identify the exact sequence of the next epidemic strains, it can predict the antigenic properties of future epidemic strains.
Antigenic evolution of contemporary H3N2 viruses

Discussion
With the current vaccine selection process (based on comparisons of sequence and antigenic data available at the time of the WHO consultations on vaccine strain selection), uncertainty remains as to whether the recommended vaccine virus will provide protective immunity against the next epidemic strain. Here, we provide a methodology that identified H1N1 and H3N2 antigenic clusters similar to those observed in nature. These data can be generated before the variants are detected in nature. In this regard, our approach is conceptually different from methods that predict which circulating variants may become dominant [32] [33] [34] [35] . Our method may therefore improve the current WHO influenza vaccine selection process. These in vitro selection studies are highly predictive of the antigenic evolution of H1N1 and H3N2 viruses in human populations. Hence, a limited number of experimental antigenic screens may be sufficient to identify potential future clusters. We found that genetic background can be important for antigenic evolution, as with the SY97-FU02 antigenic cluster transition. To put methods like ours into practice, it will probably be necessary to keep the predictions up to date by reapplying the methodology as new clades emerge. We cannot predict the HA sequence of the next epidemic strain and (compensatory) mutations in NA may also affect antigenicity. However, our methodology may be sufficient to predict the next antigenic cluster for proactive vaccine development.
Methods
Viruses and cells. 293T human embryonic kidney cells were maintained in DMEM supplemented with 10% fetal bovine serum. MDCK cells were grown in MEM containing 5% newborn calf serum. After infection with influenza viruses, MDCK cells were maintained in MEM containing 0.3% BSA and 0.5 µg ml Table 6 ).
Generation of reassortant viruses possessing HA and NA genes derived from A (H1N1)pdm09 field strains. Plasmids for the expression of the HA and NA genes of field strains were generated by site-directed PCR mutagenesis using cDNAs for the In vitro selection of antigenic escape mutants from A(H1N1)pdm09 or H3N2 virus libraries. Virus libraries were mixed with undiluted or twofold serial dilutions of the respective ferret or human sera, with the exception of the H3N2 TX/50 virus library, which was mixed with individual or mixed human sera and incubated at 4°C overnight. The virus-serum mixtures were diluted and subjected to plaque assays in MDCK cells grown in six-well plates. Antigenic escape variants were isolated from wells that showed inhibition of virus infection (<10 plaques per well) and the HA genes of the isolated viruses were sequenced.
Animal experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of WisconsinMadison. The facilities where this research was conducted are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). The animal experiments described in this study were not designed to generate data sets for statistical analysis. Hence, the sample size was small, and randomization and blinding were not carried out. Challenge experiments in ferrets. Six-to ten-month-old female ferrets (Triple F Farms) that were serologically negative by HI assay for currently circulating human influenza viruses were infected by intranasal inoculation with 500 p.f. (Fig. 4 and Supplementary Fig. 11 ). The nasal washes of the challenged ferrets were collected daily from day 1 to day 8 post-challenge. Virus titres in the nasal washes were determined using plaque assay in MDCK cells.
Generation of ferret antisera. We used six-to ten-month-old female ferrets (Triple F Farms) that were serologically negative by HI assay for currently circulating human influenza viruses. One or two ferrets per group were anaesthetized intramuscularly with ketamine and xylazine (5-30 mg and 0.2-6 mg per kg of body weight, respectively) and inoculated intranasally with 10 7 p.f.u. (500 µl) of wild-type or mutant A(H1N1)pdm09, seasonal H1N1, swine H1N1 or human H3N2 virus. Three to four weeks later, ferrets were euthanized and sera were collected for subsequent use in HI assays or the selection of escape mutants.
Antiserum treatment. Human or ferret serum (100 µl) was treated with 300 µl of receptor-destroying enzyme (RDE; Denka Seiken Co.) at 37°C for 18-24 h. To denature the RDE solution, the serum-RDE mixture was incubated at 56°C for 30-60 min. After denaturation, 600 µl sterile PBS and 100 µl pelleted turkey red blood cells (TRBCs) were added and the mixture was incubated at room temperature for 60 min. During that time, the suspension was mixed every 10 min. The mixture was then centrifuged at 3,000 r.p.m. at 4°C for 5 min. Supernatants were aliquoted and stored at −20°C for use in HI assays. To confirm that all non-specific binding had been removed, 25 µl PBS and 25 µl treated serum were mixed with 50 µl 0.5% TRBCs and incubated at room temperature for 45 min. If no hemagglutination was detected, the serum could be used for HI assays; otherwise, the antiserum treatment was repeated.
HI assays. HI titrations were performed in 96-well U bottom microtitre plates (Thermo Scientific). Sera were serially diluted twofold with PBS and then mixed with the amount of virus equivalent to eight haemagglutination units, followed by incubation at room temperature for 30 min. Finally, 50 µl 0.5% TRBCs were added. To screen TX/50 variants, sera were serially diluted twofold with PBS containing a final concentration of 20 nM oseltamivir, mixed with the amount of virus equivalent to four haemagglutination units and incubated at room temperature for 30 min. Finally, 50 µl 0.75% guinea pig red blood cells with 20 nM oseltamivir was added. Serum, virus and erythrocytes were gently mixed and incubated at room temperature for 45 min. Titres were recorded as the inverse of the highest antibody dilution that inhibited eight or four agglutinating units of virus, respectively.
Antigenic cartography of escape mutants. Antigenic maps were constructed using the antigenic cartography method 8 . The HI titres were mathematically transformed to create a table of antigenic distances, using the equation D ij = b − log 2 (H ij ), where H ij is the titre of antigen i against serum j, and b is the logarithm of the maximum titre against serum j. The error function (D ij − d ij ) 2 was minimized, where d ij is the Euclidean distance between two points on the map. Sequence analysis. Viral RNA was extracted from MDCK cell supernatant or purified plaques using the QIAmp viral RNA mini kit (Qiagen) or the MagMAX-96 Viral RNA Isolation Kit (Ambion). cDNAs were synthesized from vRNAs by reverse transcription with Uni12 primer 37 and amplified by PCR with gene-specific primers. Sequencing was performed on an Applied Biosystems DNA analyser at the Biotechnology Center of the University of Wisconsin-Madison. 
